A Positive immune response against SARS-CoV-2 was demonstrated by the preclinical evaluation of MRT5500

Sanofi Pasteur recently announced the preclinical results for an mRNA-based vaccine candidate against SARS-CoV-2 – MRT5500.

A positive immune response profile against SARS-CoV-2 was demonstrated by the preclinical evaluation of MRT5500; thus, supporting the choice of MRT5500 to enter clinical development.

Within the 4th quarter of 2020, a Phase I / II clinical trial is scheduled to begin.

Executive Vice President and Global Head of Sanofi Pasteur, Thomas Triomphe, stated: “To tackle this global pandemic we must look to both the strong knowledge we have from years of infectious disease expertise and the promise of new, innovative technologies. Today’s presentation of these positive results is another development milestone for providing a safe and effective potential vaccine against SARS-CoV2 and shows how promising this technology is. We are looking forward to working on next steps with our partner Translate Bio to bring this technology to people worldwide.”

Chief Executive Officer, Translate Bio, Ronald Renaud, stated: “The rapid development of effective vaccines to address the COVID-19 pandemic continues to be an urgent global public health need and I am encouraged by the progress we’ve made to date with our partner Sanofi Pasteur toward the development of a promising mRNA vaccine candidate. The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favourable immune response in both mice and non-human primates. Importantly, these results provide additional support for using our mRNA platform to potentially expedite the development of alternative approaches to traditional vaccines.”